Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis
Abstract
Background Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported.Materials and methods We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated.Results Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P < .001).Conclusion Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most patients can be rechallenged with lenalidomide without recurrence of rash; in rare cases in which rashes recur, management with desensitization strategies involving gradual titration from low starting doses has been effective.
“Most patients can be rechallenged with lenalidomide without recurrence of rash; in rare cases in which rashes recur, management with desensitization strategies involving gradual titration from low starting doses has been effective136.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [136]
Cites
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1970 · Cited by 792 · see citing works
Self-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648 · see citing works
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L. P., Schiffer, C. A., Stone, R. M., Greenberg, P. L., et al. (2007) · Blood · doi:10.1182/blood-2007-01-068833 · Cited by 424 · see citing works
Chanan-Khan, A. A., Miller, K. C., Musial, L., Lawrence, D. D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414 · see citing works
Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R. J., Polikoff, J. A., Bouabdallah, R., Haïoun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392 · see citing works
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G. R., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., PIETRONIGRO, D. D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3429 · Cited by 371 · see citing works
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J. E., Verstovšek, S., Mesa, R. A., Thomas, D. A., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D. M., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253 · see citing works
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Chen, C. I., Bergsagel, P. L., Paul, H. K., Xu, W. L., Lau, A., Dave, N., Kukreti, V., Wei, E. N., Leung-Hagesteijn, C., Li, Z., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8133 · Cited by 139 · see citing works
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Dimopoulos, M. A., Palumbo, A. P., Attal, M., Beksaç, M., Davies, F. E., Delforge, M., Einsele, H., Hájek, R., Harousseau, J., da Costa, F. L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.3 · Cited by 118 · see citing works
Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma
Dueck, G., Chua, N. S., Prasad, A., Finch, D. L., Stewart, D., White, D. J., van der Jagt, R., Johnston, J. B., Belch, A. R., & Reiman, T. (2010) · Cancer · doi:10.1002/cncr.25377 · Cited by 98 · see citing works
Dermatologic Adverse Effects of Lenalidomide Therapy for Amyloidosis and Multiple Myeloma
Sviggum, H. P., Davis, M. D. P., Rajkumar, S. V., et al. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.10.1298 · Cited by 93 · see citing works
Dermatologic side effects of thalidomide in patients with multiple myeloma
Hall, V. C., el‐Azhary, R. A., Bouwhuis, S. A., et al. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.87 · Cited by 84 · see citing works
Management of treatment-related adverse events in patients with multiple myeloma
Mateos, M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70009-8 · Cited by 70 · see citing works
Sharma, R. A., Steward, W. P., Daines, C. A., Knight, R., O'Byrne, K. J., & Dalgleish, A. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.018 · Cited by 51 · see citing works
Castaneda, C. P., Brandenburg, N. A., Bwire, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3737 · Cited by 45 · see citing works
Nardone, B., Nicholson, K. M., Newman, M. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0421 · Cited by 44 · see citing works
Self-citationLenalidomide for the treatment of relapsed and refractory multiple myeloma
Görgün, G., van de Donk, N. W. C. J., Groen, R. W. J., Jakubı́ková, J., Mitsiades, C. S., Hideshima, T., Richardson, P. G. G., Nijhof, Raymakers, Lokhorst, H. M., et al. (2012) · Cancer Management and Research · doi:10.2147/cmar.s27087 · Cited by 38 · see citing works
Current therapeutic uses of lenalidomide in multiple myeloma
Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.2.171 · Cited by 37 · see citing works
Role of Lenalidomide in the Treatment of Myelodysplastic Syndromes
Komrokji, R. S., & List, A. F. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.04.015 · Cited by 21 · see citing works
Wäsch, R., Jakob, T., Technau, K., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1235-y · Cited by 17 · see citing works
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Alegre, A. M., Vicuña, I., & Aguado, B. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7275 · Cited by 8 · see citing works
Breccia, M., Cannella, L., Latagliata, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5083 · Cited by 6 · see citing works
Lenalidomide following rituximab and fludarabine in untreated CLL.
Ujjani, C. S., Jamshed, S., Fitzpatrick, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.6558 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
Lee, M. J., Wickner, P., Fanning, L., Schlossman, R., Richardson, P., Laubach, J., & Castells, M. (2014) · British Journal of Haematology · doi:10.1111/bjh.12925 · Cited by 31 · see citing works
- Authors
- Nardone, B., Wu, S., Garden, B. C., West, D. P., Reich, L. M., & Lacouture, M. E.
- Affiliations
- Northwestern University (US)
- Stony Brook School (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Lacouture, Mario E.
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 13
- Issue
- 4
- Pages
- 424-429
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W2136993970
- Cited by
- 44
- References
- 25
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 8 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 3
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Lymphoma Myeloma & Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- lenalidomide, rash, cutaneous adverse events, multiple myeloma, myelodysplastic syndrome, drug toxicity, incidence, adverse drug reactions
- MeSH terms
- Lenalidomide, Exanthema, Humans, Multiple Myeloma, Thalidomide, Incidence, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
